Introduction This Company Analysis examines the current position and future outlook for Wyeth in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.
Reasons to Purchase Benchmark Wyeths performance against key rivals in the ethical pharmaceutical sector
Learn how the patent expiry of the leading depression product Effexor will affect Wyeth’s medium-term outlook
Understand the impact of Wyeth’s new product launches DVS-233 (depression), Tygacil (bacterial infections) and Bazedoxifene (women’s health)
